Discovery of novel 5-oxa-2,6-diazaspiro[3.4]oct-6-ene derivatives as potent, selective, and orally available somatostatin receptor subtype 5 (SSTR5) antagonists for treatment of type 2 diabetes mellitus.

导出原文传递

翻译打印收藏纠错

第一作者： Hideki,Hirose

第一单位： Research Division Medicinal Chemistry Laboratory, SCOHIA PHARMA, Inc., 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-8555, Japan. Electronic address: hideki.hirose@scohia.com.

作者： Hideki,Hirose ^[1] ; Takeshi,Yamasaki ^[2] ; Masaki,Ogino ^[3] ; Ryo,Mizojiri ^[2] ; Yumiko,Tamura-Okano ^[2] ; Hiroaki,Yashiro ^[2] ; Yo,Muraki ^[2] ; Yoshihide,Nakano ^[4] ; Jun,Sugama ^[3] ; Akito,Hata ^[2] ; Shinji,Iwasaki ^[2] ; Masanori,Watanabe ^[3] ; Tsuyoshi,Maekawa ^[3] ; Shizuo,Kasai ^[3]

作者单位： Research Division Medicinal Chemistry Laboratory, SCOHIA PHARMA, Inc., 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-8555, Japan. Electronic address: hideki.hirose@scohia.com. ^[1] Research Division, Takeda Pharmaceutical Co., Ltd., Shonan Research Center, 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-8555, Japan. ^[2] Research Division Medicinal Chemistry Laboratory, SCOHIA PHARMA, Inc., 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-8555, Japan. ^[3] Global Procurement, Takeda Pharmaceutical Co., Ltd., 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-8555, Japan. ^[4]

关键词 Anti-diabetic drug OGTT SSTR5 SSTR5 antagonist Somatostatin hERG inhibition